CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05446506
NCT05446506N/ACompleted

Comparative Study for Serum Levels of Otolin-1 and Vitamin D in pre-and Post-treatments of Patients With Benign Paroxysmal Positional Vertigo

Chiang Mai University·observational·Posted Jul 6, 2022·Updated Aug 31, 2023

In Brief

An observational study for Benign Paroxysmal Positional Vertigo. Completed, enrolled 21 participants across 1 site.

Detailed Summary

BPPV is the most common cause of vertigo. The pathophysiology of BPPV has not been cleared, several studies show that symptoms are caused by the displacement of otoconia from the macula of the utricle into the semicircular canals. These calcium carbonate particles then stimulate non-physiological movement of the endolymph leading to a false sensation of angular acceleration. Biomarkers represent measurable products of biological processes, thus making an assessment of those processes more practical. Biomarkers in circulation are powerful indicators of normal and pathological biological processes, as well as, responses to pharmacological treatments. The inner ear-inclusive protein that has been published included Otolin-1, Otoconin-90/95, Prestin, Otoancorin, Otogelin, α-tectorin, β-tectorin and Cochlin.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesThailand
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 6, 2022
Enrollment StartJan 13, 2021
Primary CompletionSep 30, 2022
Study CompletionFeb 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.0 years ago